First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.